- Home
- NXL vs MYNZ Comparison
NXL vs MYNZ Comparison
Compare NXL & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- MYNZ
- Stock Information
- Founded
- NXL 2010
- MYNZ 2021
- Country
- NXL United States
- MYNZ Germany
- Employees
- NXL N/A
- MYNZ N/A
- Industry
- NXL Medical Specialities
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- NXL Health Care
- MYNZ Health Care
- Exchange
- NXL Nasdaq
- MYNZ Nasdaq
- Market Cap
- NXL 10.0M
- MYNZ 11.2M
- IPO Year
- NXL 2022
- MYNZ 2021
- Fundamental
- Price
- NXL $3.16
- MYNZ $4.83
- Analyst Decision
- NXL Hold
- MYNZ Hold
- Analyst Count
- NXL 1
- MYNZ 2
- Target Price
- NXL N/A
- MYNZ N/A
- AVG Volume (30 Days)
- NXL 445.0K
- MYNZ 135.3K
- Earning Date
- NXL 11-08-2024
- MYNZ 10-21-2024
- Dividend Yield
- NXL N/A
- MYNZ N/A
- EPS Growth
- NXL N/A
- MYNZ N/A
- EPS
- NXL N/A
- MYNZ N/A
- Revenue
- NXL $162,078.00
- MYNZ $917,203.00
- Revenue This Year
- NXL $56.86
- MYNZ $21.95
- Revenue Next Year
- NXL $167.44
- MYNZ $30.77
- P/E Ratio
- NXL N/A
- MYNZ N/A
- Revenue Growth
- NXL 26.00
- MYNZ 16.23
- 52 Week Low
- NXL $0.25
- MYNZ $0.18
- 52 Week High
- NXL $4.49
- MYNZ $7.95
- Technical
- Relative Strength Index (RSI)
- NXL 51.05
- MYNZ 53.87
- Support Level
- NXL $2.55
- MYNZ $3.86
- Resistance Level
- NXL $3.11
- MYNZ $6.81
- Average True Range (ATR)
- NXL 0.32
- MYNZ 0.74
- MACD
- NXL 0.03
- MYNZ -0.09
- Stochastic Oscillator
- NXL 70.71
- MYNZ 32.88
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.